We are investigating how drug resistance evolves in bowel and gastro-oesophageal cancers, how these tumour types can be treated more effectively through novel immunotherapies and targeted drugs, and how treatment sensitivity and resistance can be predicted.
Our main research areas are focused on understanding the evolution of Barrett’s oesophagus to cancer, field cancerisation of the human stomach, and clonal expansion in ductal carcinoma in situ of the human breast.
My research interests include clonal evolution in colorectal adenomas and inflammation-associated cancer, the nature of Barrett’s glands, and the design of methods to explore neutral drift in stem cell divisions in normal human tissues.
My research focuses on the use of patient-derived organoid co-cultures and genome wide CRISPR screens to unravel tumour intrinsic gene networks controlling resistance to CD3 bispecific antibodies in colorectal cancer, and possibly applicable to other tumour types.
My research aims to understand the mechanisms through which long noncoding RNAs can control genome stability in cancer.
My research activity aims to characterise lncRNAs involved in the maintenance of genomic stability and to understand how their dysregulation can lead to cancer development.
My research in Prof Balkwill’s group focuses on imaging tumour-associated macrophages and other immune cells in live ex vivo tumour slices, in order to assess their behaviour and the impact of immunotherapies on the live tumour microenvironment.